Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Metabolic changes in the rodent brain after acute administration of salvinorin A.

Hooker JM, Patel V, Kothari S, Schiffer WK.

Mol Imaging Biol. 2009 May-Jun;11(3):137-43. doi: 10.1007/s11307-008-0192-x. Epub 2009 Jan 9.

2.

Highly selective non-opioid kappa opioid receptor (KOR) agonist salvinorin A protects against forebrain ischemia-induced brain injury in rats.

Xin J, Zhang Y, He Z, Wang Z.

Brain Res. 2016 Apr 15;1637:168-76. doi: 10.1016/j.brainres.2016.02.024. Epub 2016 Feb 21.

PMID:
26907190
3.

Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.

Placzek MS, Van de Bittner GC, Wey HY, Lukas SE, Hooker JM.

Neuropsychopharmacology. 2015 Dec;40(13):2865-72. doi: 10.1038/npp.2015.159. Epub 2015 Jun 10.

4.

Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.

Braida D, Capurro V, Zani A, Rubino T, Viganò D, Parolaro D, Sala M.

Br J Pharmacol. 2009 Jul;157(5):844-53. doi: 10.1111/j.1476-5381.2009.00230.x. Epub 2009 May 5.

5.

Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Hooker JM, Munro TA, Béguin C, Alexoff D, Shea C, Xu Y, Cohen BM.

Neuropharmacology. 2009 Sep;57(4):386-91. doi: 10.1016/j.neuropharm.2009.06.044. Epub 2009 Jul 8.

6.

Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.

Gehrke BJ, Chefer VI, Shippenberg TS.

Psychopharmacology (Berl). 2008 Apr;197(3):509-17. doi: 10.1007/s00213-007-1067-6. Epub 2008 Feb 2.

7.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

Béguin C, Potter DN, Dinieri JA, Munro TA, Richards MR, Paine TA, Berry L, Zhao Z, Roth BL, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. Epub 2007 Oct 19.

8.

Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping.

Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K.

Ann Nucl Med. 2008 Apr;22(3):191-200. doi: 10.1007/s12149-007-0099-7. Epub 2008 May 23.

PMID:
18498034
9.

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Carlezon WA Jr, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM.

J Pharmacol Exp Ther. 2006 Jan;316(1):440-7. Epub 2005 Oct 13.

10.

Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.

Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH.

Behav Pharmacol. 2005 Dec;16(8):627-33.

PMID:
16286814
11.

Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA, Twine CE Jr, Thomas BF, Gilliam AF, Gilmour BP, Carroll FI, Wiley JL.

Psychopharmacology (Berl). 2010 Jun;210(2):275-84. doi: 10.1007/s00213-010-1827-6. Epub 2010 Mar 31.

12.

Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets.

Wang Z, Ma N, Riley J, Armstead WM, Liu R.

PLoS One. 2012;7(7):e41724. doi: 10.1371/journal.pone.0041724. Epub 2012 Jul 24.

14.

Statistical parametric maps of ¹⁸F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study.

Prieto E, Collantes M, Delgado M, Juri C, García-García L, Molinet F, Fernández-Valle ME, Pozo MA, Gago B, Martí-Climent JM, Obeso JA, Peñuelas I.

Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2228-37. doi: 10.1007/s00259-011-1905-y. Epub 2011 Aug 27.

PMID:
21874322
15.

Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: a small animal PET imaging study with 18F-FDG.

Nguyen VH, Verdurand M, Dedeurwaerdere S, Wang H, Zahra D, Gregoire MC, Zavitsanou K.

Brain Res Bull. 2012 Feb 10;87(2-3):172-9. doi: 10.1016/j.brainresbull.2011.11.011. Epub 2011 Dec 1.

PMID:
22155282
16.

Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA Jr.

Neuropsychopharmacology. 2008 Oct;33(11):2676-87. doi: 10.1038/sj.npp.1301659. Epub 2008 Jan 9.

17.

[Regional cerebral glucose metabolism associated with ataxic gait--an FDG-PET activation study in patients with olivopontocerebellar atrophy].

Mishina M, Senda M, Ohyama M, Ishii K, Kitamura S, Terashi A.

Rinsho Shinkeigaku. 1995 Nov;35(11):1199-204. Japanese.

PMID:
8720328
18.

Detection of visual activation in the rat brain using 2-deoxy-2-[(18)F]fluoro-D: -glucose and statistical parametric mapping (SPM).

Soto-Montenegro ML, Vaquero JJ, Pascau J, Gispert JD, García-Barreno P, Desco M.

Mol Imaging Biol. 2009 Mar-Apr;11(2):94-9. doi: 10.1007/s11307-008-0179-7. Epub 2008 Nov 27.

PMID:
19037612
19.

Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.

Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M.

Biol Psychiatry. 2008 Feb 1;63(3):286-92. Epub 2007 Oct 24.

PMID:
17920565
20.

Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.

Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M.

Nucl Med Commun. 2001 Aug;22(8):889-97.

PMID:
11473208

Supplemental Content

Support Center